Olivia's mailing address filed with the SEC is C/O REVANCE THERAPEUTICS, INC, 1222 DEMONBREUN STREET, 20TH FLOOR, NASHVILLE, TN, 37203.
Over the last 11 years, insiders at Revance Therapeutics Inc have traded over $29,070,398 worth of Revance Therapeutics Inc stock and bought 136,530 units worth $2,014,047 . The most active insiders traders include Vlad Coric, Julian S Gangolli, eAngus C. Russell. On average, Revance Therapeutics Inc executives and independent directors trade stock every 31 days with the average trade being worth of $83,132. The most recent stock trade was executed by Erica Jordan on 16 April 2024, trading 2,392 units of RVNC stock currently worth $9,090.
revance therapeutics, inc. is a specialty biopharmaceutical company focused on the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic indications. the company is leveraging its proprietary portfolio of botulinum toxin compounds combined with its patented transmts® peptide delivery system to address unmet needs in the $3 billion neurotoxin market. revance's proprietary transmts technology enables delivery of botulinum toxin a through two novel dose formulations, a needle-free topical form and an injectable form that may localize the drug to the site of injection resulting in a more targeted and potentially longer lasting delivery. revance is currently pursuing clinical development for two product candidates, topical rt001 and injectable rt002, in a broad spectrum of aesthetic and therapeutic indications. rt001 is a topical gel, which has the potential to be the first commercially available non-injectable dose form
Revance Therapeutics Inc executives and other stock owners filed with the SEC include: